Diplomat Pharmacy, Inc. (NYSE:DPLO) had its target price hoisted by Needham & Company LLC from $23.75 to $24.00 in a research report report published on Wednesday, MarketBeat Ratings reports. Needham & Company LLC currently has a buy rating on the stock.
Several other research analysts have also commented on DPLO. Zacks Investment Research lowered shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Monday, July 17th. BidaskClub lowered shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Monday, July 31st. TheStreet raised shares of Diplomat Pharmacy from a d+ rating to a c- rating in a research note on Thursday, August 10th. Robert W. Baird reiterated a buy rating and set a $20.00 target price on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. Finally, Mizuho set a $16.00 target price on Diplomat Pharmacy and gave the stock a hold rating in a research report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Hold and an average price target of $20.06.
Diplomat Pharmacy (DPLO) traded down $0.53 during mid-day trading on Wednesday, hitting $19.66. 333,700 shares of the company were exchanged, compared to its average volume of 474,129. Diplomat Pharmacy has a 1 year low of $12.25 and a 1 year high of $21.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.88 and a current ratio of 1.34. The stock has a market capitalization of $1,354.04, a price-to-earnings ratio of 25.53, a PEG ratio of 3.54 and a beta of 0.74.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.16 billion. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. Diplomat Pharmacy’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.21 earnings per share. research analysts anticipate that Diplomat Pharmacy will post 0.85 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Needham & Company LLC Raises Diplomat Pharmacy, Inc. (DPLO) Price Target to $24.00” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/11/12/needham-company-llc-raises-diplomat-pharmacy-inc-dplo-price-target-to-24-00.html.
A number of institutional investors have recently made changes to their positions in the business. Frontier Capital Management Co. LLC raised its holdings in Diplomat Pharmacy by 4.1% in the second quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock worth $84,023,000 after purchasing an additional 221,769 shares in the last quarter. BlackRock Inc. raised its holdings in Diplomat Pharmacy by 158,977.3% in the first quarter. BlackRock Inc. now owns 5,548,617 shares of the company’s stock worth $88,501,000 after purchasing an additional 5,545,129 shares in the last quarter. Janus Henderson Group PLC bought a new position in Diplomat Pharmacy in the second quarter worth about $67,476,000. Vanguard Group Inc. raised its holdings in Diplomat Pharmacy by 5.4% in the second quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock worth $60,342,000 after purchasing an additional 210,334 shares in the last quarter. Finally, Davis Selected Advisers raised its holdings in Diplomat Pharmacy by 4.4% in the second quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock worth $25,219,000 after purchasing an additional 71,846 shares in the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.